SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field…
Top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), expected March / April 2024On…
- Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024 CHARLOTTESVILLE, Va., March 21,…
Four Phase 2 investigator-initiated studies of TNX-1900 (intranasal potentiated oxytocin) are ongoing for pediatric obesity, binge eating disorder, bone health…
CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31,…
Medical Review Committee approved initiation of recruitment of next cohort of patients, in alignment with dose optimization protocol First patient…
ZURICH, SWITZERLAND / ACCESSWIRE / March 20, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage…
- Study demonstrates alpha-synuclein biomarker can be detected in 93-100% of patients with clinically defined pathologies using simple skin biopsy…
DALLAS, TX and MARTINSRIED, GERMANY / ACCESSWIRE / March 20, 2024 / Celanese Corporation (NYSE:CE), a global specialty materials and…
Agreement terms to include payment of double-digit royalties to Jaguar on all Crofelemer products sold in the licensed territorySAN FRANCISCO,…